| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.19 mm | 1.19 mm | 1.19 mm | 1.19 mm | 1.19 mm | 1.19 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 643.13 k | 2.18 mm | 1.21 mm | 845.41 k |
| Cash used (since last report) | n/a | n/a | 3.44 mm | 11.68 mm | 6.47 mm | 4.52 mm |
| Cash remaining | n/a | n/a | -2.25 mm | -10.48 mm | -5.28 mm | -3.33 mm |
| Runway (months of cash) | n/a | n/a | -3.5 | -4.8 | -4.4 | -3.9 |
| 13F holders | Current |
|---|---|
| Total holders | 29 |
| Opened positions | 6 |
| Closed positions | 1 |
| Increased positions | 5 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 180.43 mm |
| Total shares | 15.99 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| PMCB PharmaCyte Biotech | 11.56 mm | $23.13 mm |
| Caroline C Williams | 3.75 mm | $9.26 mm |
| Intracoastal Capital | 364.96 k | $2.21 mm |
| Iroquois Capital Management | 187.42 k | $0.00 |
| MS Morgan Stanley | 63.19 k | $72.66 mm |
| Susquehanna International | 22.87 k | $26.31 mm |
| Geode Capital Management | 16.57 k | $19.06 mm |
| Vanguard | 14.00 k | $16.10 mm |
| Tower Research Capital | 4.09 k | $4.70 mm |
| BlackRock | 3.80 k | $4.37 mm |
